Award
NIH Reporter #5R41AI188733-02
A novel Th17-enhancing adjuvant and conserved antigen for protection against viral/bacterial co-infection
Recipient
VISHENARY, LLC
Award Amount
$283,001.00
Ceiling
$283,001.00
Awarded
August 19, 2026
Identifier
5R41AI188733-02
Award for vaccine development and testing to create a Th17-enhancing adjuvant and conserved antigen targeting viral and bacterial co-infections, funded by NIAID under a Phase I STTR program.
Description
Development of a mucosal Th17-based vaccine for clinical use focusing on a vaccine candidate with Th17 adjuvant Romidepsin (RMD) and conserved antigen protein 0259. The project includes preclinical safety and efficacy studies and is part of a Phase I Small Business Technology Transfer Research (STTR) program.